2,717 results match your criteria Breast[Journal]


De-escalation of complexity in oncoplastic breast surgery: Case series from a specialized breast center.

Breast 2019 Apr 9;46:12-18. Epub 2019 Apr 9.

Multidisciplinary Breast Unit, Azienda Ospedaliera Cannizzaro, Catania, Italy.

Introduction: Oncoplastic breast surgery has evolved the surgical treatment of breast cancer over the past two decades. This practice still lacks validation and poses several dilemmas in terms of safety, local and systemic control, timing of adjuvant treatments and cost-effectiveness. Our case series investigates the effects of a reduced surgical complexity on cosmetic results and quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.04.002DOI Listing

Patient-reported health problems and healthcare use after treatment for early-stage breast cancer.

Breast 2019 Apr 4;46:4-11. Epub 2019 Apr 4.

Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands; Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, the Netherlands.

Background: A clear picture of treatment-related health problems following breast cancer treatment is useful in anticipating the informational and other needs of patients during follow-up. This study aimed to identify treatment-related health problems in breast cancer patients up to five years after diagnosis. Secondly, the use of care associated with these health problems was identified. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193047
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.03.010DOI Listing
April 2019
3 Reads

Breast cancer medical malpractice litigation in New York: The past 10 years.

Breast 2019 Apr 3;46:1-3. Epub 2019 Apr 3.

Brooklyn Law School.

Medical error is a leading cause of preventable death in the U.S., with diagnostic errors comprising the majority of errors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193047
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.03.009DOI Listing
April 2019
1 Read

Low eicosapentaenoic acid and gamma-linolenic acid levels in breast adipose tissue are associated with inflammatory breast cancer.

Breast 2019 Apr 1;45:113-117. Epub 2019 Apr 1.

Department of Gynecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau. 2 Boulevard Tonnellé, 37044, Tours, France; INSERM UMR1069 « Nutrition, Growth and Cancer », 10 Boulevard Tonnellé, 37032, Tours, France; University of Tours, 10 Boulevard Tonnellé, 37032, Tours, France. Electronic address:

Objective: Since it is thought that breast adipose tissue could influence breast cancer clinical presentation, we wanted to characterize specifically the relationship between breast adipose tissue fatty acid profile and Inflammatory Breast cancer (IBC).

Methods: Two hundred thirty-four women presenting with breast cancer were managed in our centre between January 2009 and December 2011. Breast adipose tissue specimens were collected during breast surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.04.001DOI Listing

Acceptance of contralateral reduction mammoplasty after oncoplastic breast conserving surgery: A semi-structured qualitative interview study.

Breast 2019 Mar 25;45:97-103. Epub 2019 Mar 25.

Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:

Objectives: Oncoplastic breast conserving surgery (BCS) frequently induces asymmetry. Contralateral reduction mammoplasty (CRM) is therefore part of the oncoplastic approach. Our patients frequently declined CRM when offered as a second-stage procedure after the completion of adjuvant treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.008DOI Listing
March 2019
2 Reads

Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis.

Breast 2019 Mar 23;45:104-112. Epub 2019 Mar 23.

Department of Breast Surgery, Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China. Electronic address:

Background: We aimed to validate the clinical significance of locoregional surgery in improving the prognosis of primary metastatic breast cancer (pMBC).

Methods: We conducted a population-based retrospective study by analyzing clinical data obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Stratification analysis was employed to assess the effect of breast surgery on breast cancer-specific survival and overall survival. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193005
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.03.006DOI Listing
March 2019
4 Reads

Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice.

Breast 2019 Mar 11;45:89-96. Epub 2019 Mar 11.

AOU Città della Salute e della Scienza, CPO Piemonte and EUSOMA Data Centre, Turin, Italy.

Background: Data from recently published trials have provided practice-changing recommendations for the surgical approach to the axilla in breast cancer. Patients with T1-2 lesions, treated with breast conservation, who have not received neoadjuvant chemotherapy and have 1-2 positive sentinel nodes (Z0011-criteria) may avoid axillary lymph node dissection (ALND). We aim to describe the dissemination of this practice in Europe over an extended period of time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.002DOI Listing

Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.

Breast 2019 Mar 12;45:82-88. Epub 2019 Mar 12.

Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Objectives: This study aimed to investigate the cost-effectiveness of intensified breast cancer (BC) screening for women with a BRCA1/2 mutation aged 60-74. Simulated strategies were: (0) annual mammography as reference, (1) alternating annual mammography and MRI for women with dense breasts only; (2) addition of annual MRI for women with dense breasts only; (3) addition of annual MRI for all women.

Materials And Methods: A validated micro-simulation model of invasive BC was updated and validated for interval BC rates and tumor size distribution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.004DOI Listing

Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenarios.

Breast 2019 Mar 12;45:75-81. Epub 2019 Mar 12.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK.

Many studies have found evidence of socioeconomic differences in breast cancer survival. This study aimed to quantify the impact of removing differences in stage distribution and stage-specific relative survival between education groups in Swedish women with breast cancer. Using information from a breast cancer research database, the study population contained 62 121 women diagnosed with breast cancer in three healthcare regions of Sweden from 1992 to 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.005DOI Listing

Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer.

Breast 2019 Mar 8;45:70-74. Epub 2019 Mar 8.

Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands; Dutch Expert Centre for Screening, Nijmegen, the Netherlands.

Purpose: Follow-up schemes in breast cancer survivors are predominantly consensus-based. To determine evidence-based follow-up intervals, estimates of sensitivity of the screening test(s) and duration of the preclinical detectable phase (PCDP) are key. We estimated the sensitivity and the duration of the PCDP of clinical breast examination (CBE) and mammography for the detection of contralateral second breast cancers (CBC) in breast cancer survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.003DOI Listing

Towards mm-wave spectroscopy for dielectric characterization of breast surgical margins.

Breast 2019 Feb 27;45:64-69. Epub 2019 Feb 27.

Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Purpose: The evaluation of the surgical margin in breast conservative surgery is a matter of general interest as such treatments are subject to the critical issue of margin status as positive surgical margins can undermine the effectiveness of the procedure. The relatively unexplored ability of millimeter-wave (mm-wave) spectroscopy to provide insight into the dielectric properties of breast tissues was investigated as a precursor to their possible use in assessment of surgical margins.

Methods: We assessed the ability of a mm-wave system with a roughly hemispherical sensitive volume of ∼3 mm radius to distinguish malignant breast lesions in prospectively and consecutively collected tumoral and non-tumoral ex-vivo breast tissue samples from 91 patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193002
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.008DOI Listing
February 2019
3 Reads

Tumor dormancy at bedside: A late awakening.

Breast 2019 Mar 2;45:61-63. Epub 2019 Mar 2.

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Breast cancer recurrence may occur at variable times following primary tumor removal. The corresponding event dynamics displays a structured multipeak pattern, which can be explained by the occurrence of microscopic phases of metastasis quiescence (tumor dormancy) followed by wake up, growth and timed clinical appearance. This model provides a meaningful justification of the early recurrence pattern and even explains the effectiveness of adjuvant systemic therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.001DOI Listing

Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC).

Breast 2019 Mar 7;45:56-60. Epub 2019 Mar 7.

IEO, Milano, Italy.

Background: Breast angiosarcoma is a malignant mesenchymal neoplasm, which accounts for approximately 2% of all soft tissue sarcomas. Secondary breast angiosarcoma (SBA) may be related to chronic lymphedema after a mastectomy with lymph node dissection (Stewart Treves syndrome) and previous radiotherapy for complications from breast radiation treatment. It is a very rare condition; therefore, diagnosis and management are still a challenge. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193003
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.011DOI Listing
March 2019
3 Reads

Reply to correspondence concerning "Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer".

Breast 2019 Feb 15. Epub 2019 Feb 15.

Division of General Surgery, Department of General Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.005DOI Listing
February 2019

Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age.

Breast 2019 Mar 2;45:48-55. Epub 2019 Mar 2.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden.

Objectives: Women diagnosed with breast cancer during working age are at increased risk of permanent absence from work, but the underlying medical causes have rarely been studied. We examined the risk of cause-specific sick leave, disability pension, and the competing event death after a breast cancer diagnosis in a population-based cohort study.

Materials And Methods: From the Breast Cancer Data Base Sweden, we identified 16,603 women diagnosed with stage I-III breast cancer between 2000 and 2012, and 63,773 control women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.012DOI Listing
March 2019
1 Read

Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16).

Breast 2019 Feb 26;45:43-47. Epub 2019 Feb 26.

Department of Radiation Oncology, Korea Medical Center, Seoul, Republic of Korea.

Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT).

Materials And Methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193003
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.010DOI Listing
February 2019
8 Reads
2.381 Impact Factor

Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline.

Breast 2019 Feb 22;45:36-42. Epub 2019 Feb 22.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

The primary aim of the international advance breast cancer (ABC) guidelines are to guide treatment decisions in many different healthcare settings, but need adaptations due to different access to care. These guidelines are based on the most up-to-date evidence. However, Chinese experts have a different national condition and policies to face. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.009DOI Listing
February 2019
2 Reads
2.381 Impact Factor

"Decoding hereditary breast cancer" benefits and questions from multigene panel testing.

Breast 2019 Jan 8;45:29-35. Epub 2019 Jan 8.

Department of Genetics, Institut Curie, Paris, France; Paris Descartes Sorbonne-Paris-Cité University, Paris, France; INSERM U830, Institut Curie Paris, Paris, France. Electronic address:

Multigene panel testing for breast and ovarian cancer predisposition diagnosis is a useful tool as it makes possible to sequence a considerable number of genes in a large number of individuals. More than 200 different multigene panels in which the two major BRCA1 and BRCA2 breast cancer predisposing genes are included are proposed by public or commercial laboratories. We review the clinical validity and clinical utility of the 26 genes most oftenly included in these panels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.002DOI Listing
January 2019
2.381 Impact Factor

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.

Breast 2019 Feb 13;45:22-28. Epub 2019 Feb 13.

National Center for Tumor Disease, Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany.

Background: This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative breast cancer.

Patients And Methods: Patients were randomized 1:1 to receive docetaxel 100 mg/m on day 1 every 3 weeks in combination with sorafenib 400 mg bid or placebo on days 2-18 of each cycle until tumor progression, or unacceptable toxicity. Sorafenib/placebo could be continued at the investigator's discretion if docetaxel was stopped due to toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.002DOI Listing
February 2019
5 Reads

Homologous recombination deficiency in triple negative breast cancer.

Breast 2019 Feb 20;45:15-21. Epub 2019 Feb 20.

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, via Ripamonti 435, 20141, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, via Festa del Perdono 7, 20122, Milan, Italy.

Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9-12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.007DOI Listing
February 2019
5 Reads

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).

Breast 2019 Jan 28;45:7-14. Epub 2019 Jan 28.

Pierre Fabre Médicament, 45 Place Abel Gance, 92654, Boulogne-Billancourt, France. Electronic address:

Background: Single-agent paclitaxel and vinorelbine are recommended treatments for advanced breast cancer (ABC) non-responsive to hormone therapy and without visceral crisis. This phase II trial compared first-line oral vinorelbine versus weekly paclitaxel for ABC.

Methods: Eligible female patients had measurable locally recurrent/metastatic estrogen receptor-positive HER2-negative breast cancer and had received prior endocrine therapy (any setting) but no chemotherapy for ABC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193000
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.01.009DOI Listing
January 2019
8 Reads

Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy.

Breast 2019 Feb 15;45:1-6. Epub 2019 Feb 15.

Prevent Breast Cancer Research Unit, Manchester University Hospital NHS Foundation Trust, Manchester UK.

Aim: In breast cancer patients, post chemotherapy weight gain is linked with increased risk of cancer recurrence. We prospectively studied a cohort of premenopausal women receiving contemporary chemotherapy following a diagnosis of breast cancer to examine factors predicting weight increase.

Methods: Between May 2005 and January 2008, 523 patients from the Prospective Outcomes in Sporadic versus Hereditary (POSH) breast cancer study entered this sub-study comparing weight prior to chemotherapy and weight and waist/hip measurements 12-months following chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.006DOI Listing
February 2019

Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015.

Breast 2019 Apr 11;44:153-159. Epub 2019 Feb 11.

ANU Medical School, Australian National University, Barry Drive, Acton, ACT 0200, Australia; Health Analytics Research Centre, ACT Health, GPO Box 825, ACT 2601, Australia.

Background: Evidence suggests recent improvements in outcome in early breast cancer (EBC).

Aim: To analyse recurrence in women with EBC from our region from 1997 to 2015.

Methods: We analysed recurrence in 3,765 women with EBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.004DOI Listing

Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival.

Breast 2019 Apr 12;44:144-152. Epub 2019 Feb 12.

Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75 M. Asias Street, Goudi, 115 27, Athens, Greece. Electronic address:

Aim: To further quantify the association between physical activity (PA) after breast cancer diagnosis and all-cause mortality, breast cancer mortality and/or breast cancer recurrence.

Methods And Results: PubMed was searched until November 2017 for observational studies investigating any type of PA in association with total mortality, breast cancer mortality and/or breast cancer recurrence among women with breast cancer diagnosis. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using random-effects models for highest versus lowest categories of PA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.001DOI Listing

Non-pharmacological therapies for depressive symptoms in breast cancer patients: Systematic review and meta-analysis of randomized clinical trials.

Breast 2019 Apr 31;44:135-143. Epub 2019 Jan 31.

DPH, Instituto Nacional de Salud Pública, Av. Universidad 655, Sta. Ma. Ahuacatitlán, C.P. 62100, Cuernavaca, Morelos, Mexico. Electronic address:

Objective: Depressive symptoms are common comorbidities among breast cancer (BC) patients. Non-pharmacological therapies (NPTs) such as exercise and psychotherapy may reduce depressive symptoms; however, the evidence is inconclusive. The objective of this study is to evaluate if NPTs reduce depressive symptoms among BC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.006DOI Listing

Peptide vaccines in early breast cancer.

Breast 2019 Apr 7;44:128-134. Epub 2019 Feb 7.

IEO, European Institute of Oncology IRCCS, Milan Italy; University of Milan, Italy. Electronic address:

The immune system plays a dual role of host-protecting and tumor-promoting, as elegantly expressed by the 'cancer immunoediting' hypothesis. Although breast cancer has not been traditionally considered to be immunogenic, recently there is accumulating and solid evidence on the association between immune system and breast cancer. To mount an effective anti-tumor response, host immunosurveillance must recognize tumor-specific epitopes, thus defining the antigenicity of a tumor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193002
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.003DOI Listing
April 2019
7 Reads

Body image problems in women with and without breast cancer 6-20 years after bilateral risk-reducing surgery - A prospective follow-up study.

Breast 2019 Apr 1;44:120-127. Epub 2019 Feb 1.

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Bioclinicum J5:17, SE-171 64, Solna, Sweden. Electronic address:

Purpose: To prospectively follow-up and investigate women's perceptions of the cosmetic outcome of their implant-based breast reconstruction, body image, sexuality, anxiety/depressive symptoms, and health-related quality of life (HRQoL) 6-20 years after bilateral risk-reducing mastectomy (RRM), or complementary RRM after breast cancer diagnosis, due to increased risk of hereditary breast cancer.

Patients And Methods: Women with and without previous breast cancer diagnosis that underwent RRM between March 1997 and September 2010 were invited (n = 200). We compared 146 (73%) sets of long-term questionnaire responses (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.013DOI Listing
April 2019
1 Read

Category "viewpoints and debates" Is trastuzumab as a single agent obsolete in early breast cancer? Yes.

Breast 2019 Feb 20;43:146-148. Epub 2018 Oct 20.

Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM U1218, INSERM CIC1401, Bordeaux, France.

In 2005, two adjuvant trials revolutionised breast cancer treatment demonstrating a 50% reduction in relapses when trastuzumab was added to adjuvant chemotherapy. In order to improve further on these results three large phase III trials were conducted. ALTTO trial evaluated lapatinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.10.008DOI Listing
February 2019

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study.

Breast 2019 Apr 2;44:113-119. Epub 2019 Feb 2.

Latin American Cooperative Oncology Group, Porto Alegre, Brazil.

Objective: To describe stage I-III breast cancer (BC) molecular subtypes and outcomes among a cohort of patients from Brazil.

Methods: AMAZONA study is a retrospective cohort conducted from June 2008 to January 2009 including women of at least 18 years old, with histologically proven breast cancer, diagnosed in 2001 (n = 2198) and 2006 (n = 2714). In this analysis, we included patients who underwent surgery, had stage I-III disease and available pathological information (n = 2296). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.008DOI Listing
April 2019
4 Reads
2.381 Impact Factor

Effects of pessimism, depression, fatigue, and pain on functional health-related quality of life in patients with resected non-advanced breast cancer.

Breast 2019 Apr 2;44:108-112. Epub 2019 Feb 2.

Department of Medical Oncology, Hospital Universitario Central of Asturias, Oviedo, Spain.

Introduction: The aim was to analyze the effects of pessimism, depression, fatigue, and pain on functional health-related quality of life (HRQoL) in patients with resected, non-advanced breast cancer.

Methods: A prospective, multicenter study was conducted in 440 breast cancer patients. They completed the Brief Symptom Inventory (BSI), the European Organization for Research and Treatment of Cancer QoL-Questionnaire-Core-30 (EORTC-QLQ-C30), and the Revised Life Orientation Test (LOT-R). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193001
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.01.012DOI Listing
April 2019
4 Reads

Taking the pulse of multidisciplinary cancer conferences for breast cancer care in Canada: A stocktake of current practice.

Breast 2019 Apr 25;44:101-107. Epub 2019 Jan 25.

Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond St, Toronto, M5B 1W8, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College ST, Toronto, ON, M5T 3M7, Canada; Division of General Surgery, Department of Surgery, University of Toronto, 149 College St, Toronto, M5T 1P5, Canada. Electronic address:

Aim: International guidelines highlight the importance of implementation supports and quality monitoring of multidisciplinary care for breast cancer. In Canada, Ontario has standards for formal multidisciplinary cancer conferences (MCCs), but other provinces/territories do not. This study aimed to stocktake MCCs for breast cancer in Canadian sites participating in the RUBY cohort study (Reducing the Burden of Breast Cancer in Young Women) to better understand variations in multidisciplinary care across Canada and to add to the international literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.007DOI Listing

The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.

Breast 2019 Apr 18;44:94-100. Epub 2019 Jan 18.

The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, CH63 4JY, UK; The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, L69 3GE, UK; Liverpool and Merseyside Academic Breast Unit, Clatterbridge Cancer Centre-The Linda McCartney Centre, Liverpool, L7 8XP, UK. Electronic address:

Purpose: The 21-gene recurrence score (Oncotype DX) (RS) informs systemic therapy decision making in ER-positive HER2-negative early breast cancer (BC). To date no study has described the more nuanced discussions that take place regarding systemic therapy or the impact of the RS on concordance in such decision making. Here we utilized a novel decision making tool to assess the impact of the RS on decision making as well as concordance of treatment recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.005DOI Listing
April 2019
2 Reads

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants.

Breast 2019 Apr 26;44:90-93. Epub 2019 Jan 26.

Breast Unit, Nuovo Ospedale di Prato, Prato, Italy.

During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.011DOI Listing

Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.

Breast 2019 Apr 20;44:81-89. Epub 2018 Dec 20.

Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address:

Objectives: In breast cancer, large tumor size, positive nodal stage and a triple-negative tumor subtype are associated with reduced survival, but the interactions between these prognostic factors are not well understood.

Material And Methods: Here we re-evaluated the impact of tumor size, nodal stage and tumor subtype on disease-free survival (DFS), overall survival (OS), distant disease-free survival (DDFS) and breast cancer specific survival (BCSS) in a retrospective analysis using data from the adjuvant SUCCESS A trial. Subgroup analyses were conducted to assess whether the effect of tumor size and nodal stage on survival depended on tumor subtype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.008DOI Listing
April 2019
1 Read

Cancer treatment effects on cognition and depression: The moderating role of physical activity.

Breast 2019 Apr 16;44:73-80. Epub 2019 Jan 16.

Department of Exercise Science, 201 Women's Building, Syracuse University, USA; Program in Neuroscience, 362 Life Sciences, Syracuse University, USA. Electronic address:

Objectives: Breast cancer survivors report significant cognitive impairments post treatment, particularly following chemotherapy. Depression may also occur post treatment and may partially mediate the effects of cancer treatment on cognition. Additionally, physical activity has been shown to mitigate treatment effects on cognition and depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.004DOI Listing
April 2019
1 Read

How do breast cancer patients experience multidisciplinary tumor conferences? - A description from the patient perspective.

Breast 2019 Apr 4;44:66-72. Epub 2019 Jan 4.

Department of Health Services Research, Faculty of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 140, 26129 Oldenburg, Germany.

Objectives: Aim of this study was to investigate the experiences of breast cancer patients who participated in multidisciplinary tumor conferences (MTCs).

Study Design: Data from two consecutive years of an annual postal survey of patients with primary breast cancer were combined. Data was collected between February and July 2015 (response rate 72%) and 2016 (response rate 73%) from N = 8893 patients (ICD-10 C50) after hospital discharge from 86 breast cancer center hospitals in North Rhine-Westphalia, Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.012DOI Listing
April 2019
1 Read

The changes of quality of life and their correlations with psychosocial factors following surgery among women with breast cancer from the post-surgery to post-treatment survivorship.

Breast 2019 Apr 4;44:59-65. Epub 2019 Jan 4.

Breast Center, National Taiwan University Hospital, Professor, Department of Surgery, Collage of Medicine, National Taiwan University, Taiwan. Electronic address:

Objectives: This 14-month study aimed to examine the changes of quality of life following breast cancer surgery and associations of such changes with depression and anxiety levels, and protective factors (attachment styles in close relationship, and meaning in life) based on positive psychology theory.

Materials And Methods: Women with breast cancer were recruited within one week of completion of breast cancer surgery. They were asked to complete several questionnaires to measure the generic and breast cancer specific quality of life, depression and anxiety levels, attachment styles in close relationship, and meaning in life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.011DOI Listing
April 2019
3 Reads

Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.

Breast 2019 Apr 8;44:52-58. Epub 2019 Jan 8.

Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway. Electronic address:

Purpose: Adjuvant endocrine therapy (ET) in breast cancer reduces recurrence risk and increases overall survival. The aim of the study was to quantify non-adherence and discontinuation to ET in postmenopausal women with breast cancer, and identify possible clinical or social risk factors.

Methods: Women with hormone-receptor positive breast cancer (N = 138), mean age 58 (SD 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.003DOI Listing
April 2019
6 Reads

A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.

Breast 2019 Apr 4;44:46-51. Epub 2019 Jan 4.

Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address:

Purpose: We aimed to assess the implementation and effectiveness of exemestane plus everolimus treatment per hospital type in real-life, shortly after approval of everolimus.

Methods: Advanced breast cancer patients treated with exemestane plus everolimus in 2012-2014 were included from the SONABRE registry. Progression-free survival (PFS) and a 12-week conditional PFS (post-hoc) were estimated by Kaplan-Meier method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.01.001DOI Listing
April 2019
12 Reads

Results of PONDx, a prospective multicenter study of the Oncotype DX breast cancer assay: Real-life utilization and decision impact in French clinical practice.

Breast 2019 Apr 3;44:39-45. Epub 2019 Jan 3.

Institut Régional du Cancer, 3 Rue de la Porte de l'hôpital, 67065, Strasbourg, France. Electronic address:

Adjuvant chemotherapy shows clear benefits in HER2-positive and triple-negative breast cancer (BC). Its benefits are less universal in BCs expressing hormone receptors. The 21-gene Oncotype DX Breast Recurrence Score test was designed for HR+, HER2- early-stage BC before decision on adjuvant chemotherapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776183035
Publisher Site
http://dx.doi.org/10.1016/j.breast.2018.12.015DOI Listing
April 2019
18 Reads

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Breast 2019 Apr 2;44:33-38. Epub 2019 Jan 2.

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.

The immune system seems to play a fundamental role in breast cancer responsiveness to chemotherapy. We investigated two peripheral indicators of immunity/inflammation, i.e. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776183035
Publisher Site
http://dx.doi.org/10.1016/j.breast.2018.12.014DOI Listing
April 2019
10 Reads
2.381 Impact Factor

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Breast 2019 Apr 20;44:29-32. Epub 2018 Dec 20.

NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA. Electronic address:

Metaplastic breast cancer (MPBC) is a rare subtype that accounts for <1% of all breast cancers. Although these are typically "triple negative," they are relatively chemotherapy-refractory compared to conventional triple negative invasive breast cancers with more aggressive features and an overall poor prognosis. MPBC is a heterogeneous group of tumors that are enriched for TP53 and PIK3CA mutations, and have been found to have high PD-L1 expression though the mechanisms underlying its immunogenicity remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.010DOI Listing
April 2019
3 Reads

Unemployment following breast cancer diagnosis: A population-based study.

Breast 2019 Apr 27;44:24-28. Epub 2018 Dec 27.

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; The Jerusalem Institute of Aging Research, Hadassah-Hebrew University Medical Center Mount Scopus, and Hebrew University-Hadassah Medical School, Mount Scopus, Jerusalem, Israel.

Objectives: The population of breast cancer survivors is growing. In Western societies, many of these women are working age, and therefore, potentially desire to return to the work force. We aimed to evaluate the unemployment risk for up to 8 years following a breast cancer diagnosis and identify contributing socio-economic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.013DOI Listing

Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management.

Breast 2019 Apr 17;44:15-23. Epub 2018 Dec 17.

Division of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy. Electronic address:

Breast cancer related lymphedema (BCRL) develops as a consequence of surgical treatment and/or radiation therapy in a significant number of breast cancer patients. The etiology of this condition is multifactorial and has not yet been completely elucidated. Risk factors include high body mass index, radical surgical procedures (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.009DOI Listing
April 2019
4 Reads

Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis.

Breast 2019 Apr 6;44:1-14. Epub 2018 Dec 6.

Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address:

Background: The risk of developing metachronous contralateral breast cancer (CBC) is a recurrent topic at the outpatient clinic. We aimed to provide CBC risk estimates of published patient, pathological, and primary breast cancer (PBC) treatment-related factors.

Methods: PubMed was searched for publications on factors associated with CBC risk. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776183032
Publisher Site
http://dx.doi.org/10.1016/j.breast.2018.11.005DOI Listing
April 2019
12 Reads

Is trastuzumab as a single agent obsolete in early breast cancer? No.

Breast 2019 Feb 19;43:142-145. Epub 2018 Dec 19.

Department of Medical Oncology, Department of Medical Oncology, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy. Electronic address:

Until very recently, the "one size fits all" approach, with trastuzumab and chemotherapy with or without endocrine therapy, has been considered standard of care in almost all patients with HER2-positive early breast cancer. The combination of trastuzumab and chemotherapy is considered an undeniable therapy in this setting, given the unquestionable clinical benefit and the favorable safety profile. This almost universal adoption of trastuzumab-based therapies in early breast cancer has led to a proportional increase of overtreated patients, thus making treatment de-escalation in HER2-positive early breast cancer one of the major and more urgent unmet clinical need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.09.002DOI Listing
February 2019

Reply to the letter "Pure or mixed type invasive lobular carcinoma; are they different from each other?"

Breast 2019 Feb 13;43:151-152. Epub 2018 Dec 13.

Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.006DOI Listing
February 2019

Pure or mixed type invasive lobular carcinoma; are they different from each other?

Authors:
Kadri Altundag

Breast 2019 Feb 10;43:151. Epub 2018 Dec 10.

MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.007DOI Listing
February 2019

Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.

Breast 2019 Feb 7;43:135-141. Epub 2018 Dec 7.

Department of Biophysics and Human Physiology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland.

Introduction: Metaplastic breast cancer (MpBC) is a rare but aggressive type of breast cancer accounting for 0.25-1% of all diagnosed invasive breast cancers. Morphologically, it is characterized by differentiation of the neoplastic epithelium into squamous cells and/or mesenchymal-looking tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.004DOI Listing
February 2019
2 Reads